Regulus employs an intellectual property strategy that both protects its microRNA drug products and provides a competitive advantage in the field of microRNA therapeutics. Through a combination of product-specific, platform-based and chemistry patents, Regulus creates multiple layers of patent protection surrounding each microRNA drug product. Additionally, Regulus has intellectual property arising from the Company’s expertise in oligonucleotide manufacturing processes, drug design, bioinformatics analysis, and biological mechanisms.

In the field of microRNA therapeutics, Regulus exclusively controls over 100 patents and patent applications directed to microRNA specific technologies, including microRNA target sequences, therapeutic uses, drug products, drug designs, and analytical methods. Additionally, Regulus has exclusive rights to over 900 patents and patent applications pertaining to oligonucleotide modifications, conjugates, and design patterns useful for use targeting microRNA for therapeutic applications.

Our technology is protected by a deep and multi-layered IP portfolio.